JSR Life Sciences LLC has launched the ‘JSR Life Sciences Corporate Venture Fund’ as part of a continued effort to identify and accelerate novel therapies and innovative technologies.
Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform, have signed a commercial license agreement to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV).
Crown Bioscience, JSR Life Sciences and Cambridge Quantum Computing (CQC) have entered a partnership agreement to explore the application of quantum technology to drive the identification of multi-gene biomarker discovery for oncology drug discovery.
The parent company of JSR Life Sciences snapped up contract research organization Crown Bioscience International for $400 million, the company announced this morning.